NCCN VERSION 2 2015

169 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-94
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
370. Wong TZ, Paulson EK, Nelson RC, et al. Practical approach to
diagnostic CT combined with PET. AJR Am J Roentgenol
2007;188:622-629. Available at:
.
371. Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast
cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds.
Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins;
2004.
372. Impact of follow-up testing on survival and health-related quality of
life in breast cancer patients. A multicenter randomized controlled trial.
The GIVIO Investigators. JAMA 1994;271:1587-1592. Available at:
373. Rosselli Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic
follow-up after treatment of primary breast cancer. A randomized trial.
National Research Council Project on Breast Cancer follow-up. JAMA
1994;271:1593-1597. Available at:
374. Smith TJ, Davidson NE, Schapira DV, et al. American Society of
Clinical Oncology 1998 update of recommended breast cancer
surveillance guidelines. J Clin Oncol 1999;17:1080-1082. Available at:
.
375. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of
recommendations for the use of tumor markers in breast and colorectal
cancer: clinical practice guidelines of the American Society of Clinical
Oncology. J Clin Oncol 2001;19:1865-1878. Available at:
.
376. Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al. Risk of breast
cancer recurrence and contralateral breast cancer in relation to BRCA1
and BRCA2 mutation status following breast-conserving surgery and
radiotherapy. Eur J Cancer 2005;41:2304-2311. Available at:
.
377. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast
cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol
2004;22:2328-2335. Available at:
.
378. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-
institutional results of breast-conserving surgery and radiotherapy in
BRCA1/2-associated stage I/II breast cancer. J Clin Oncol
2006;24:2437-2443. Available at:
.
379. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer.
Obstet Gynecol 2006;107:1475-1478. Available at:
.
380. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in
management of hot flashes in survivors of breast cancer: a randomised
controlled trial. Lancet 2000;356:2059-2063. Available at:
.
381. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot
flashes in patients who have breast cancer with venlafaxine and
clonidine: a randomized, double-blind, placebo-controlled trial. J Clin
Oncol 2011;29:3862-3868. Available at:
.
382. Kaplan M, Mahon S, Cope D, et al. Putting evidence into practice:
evidence-based interventions for hot flashes resulting from cancer
therapies. Clin J Oncol Nurs 2011;15:149-157. Available at:
.
383. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter,
randomized, cross-over clinical trial of venlafaxine versus gabapentin
for the management of hot flashes in breast cancer survivors. J Clin
Oncol 2010;28:5147-5152. Available at:
.